stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Revenue
Royalty Pharma PLC's revenue for fiscal 2025 was $2.4B, up 5.06% from $2.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.6B. Over the past ten years it has ranged from $1.8B (fiscal 2018) to $2.4B (fiscal 2025) — the current reading is the highest in ten years. Royalty Pharma PLC ranks 12th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.4B | 5.06% |
| FY2024 | $2.3B | (3.86%) |
| FY2023 | $2.4B | 5.24% |
| FY2022 | $2.2B | (2.28%) |
| FY2021 | $2.3B | 7.87% |
| FY2020 | $2.1B | 16.98% |
| FY2019 | $1.8B | 1.08% |
| FY2018 | $1.8B | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $690.1M | 2.37% |
| Jun 2026 | $674.1M | 6.91% |
| Mar 2026 | $630.6M | 1.38% |
| Dec 2025 | $622.0M | 2.08% |
| 25 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.6B |
| INCY Incyte Corporation compare | $6.0B |
| ARGX argenex SE compare | $5.9B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| RPRX Royalty Pharma PLC | $2.6B |
| INSM Insmed, Inc. compare | $1.5B |
| RVMD Revolution Medicines, Inc. compare | $209.1M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RPRX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement